TWD 68.7
(0.15%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 147.09 Million TWD | 26.99% |
2022 | 113.96 Million TWD | 45.03% |
2021 | 80.41 Million TWD | 76.96% |
2020 | 44.81 Million TWD | 31.47% |
2019 | 34.7 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 43.55 Million TWD | 146.61% |
2024 Q2 | 36.84 Million TWD | -16.52% |
2023 Q4 | 17.66 Million TWD | -45.71% |
2023 FY | - TWD | 26.99% |
2023 Q3 | 32.52 Million TWD | -39.7% |
2023 Q2 | 53.94 Million TWD | 21.02% |
2023 Q1 | 44.57 Million TWD | 103.99% |
2022 FY | - TWD | 45.03% |
2022 Q4 | 21.85 Million TWD | 0.0% |
2021 FY | - TWD | 76.96% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
DIVA Laboratories, Ltd. | 100.31 Million TWD | -46.631% |
Genetics Generation Advancement Corp. | 50.6 Million TWD | -190.681% |
Welgene Biotech Co.,Ltd. | 26.83 Million TWD | -448.12% |
Puriblood Medical Co., Ltd. | -44.01 Million TWD | 434.187% |
TFBS Bioscience Inc. | 64.15 Million TWD | -129.29% |